MA42825B1 - Anticorps se liant spécifiquement à tl1a - Google Patents
Anticorps se liant spécifiquement à tl1aInfo
- Publication number
- MA42825B1 MA42825B1 MA42825A MA42825A MA42825B1 MA 42825 B1 MA42825 B1 MA 42825B1 MA 42825 A MA42825 A MA 42825A MA 42825 A MA42825 A MA 42825A MA 42825 B1 MA42825 B1 MA 42825B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- tl1a
- disease
- cystic fibrosis
- specifically bind
- Prior art date
Links
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 abstract 1
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Sorting Of Articles (AREA)
Abstract
La présente invention concerne des anticorps variants exprimés par recombinaison qui présentent une affinité accrue pour tl1a et une puissance améliorée par rapport à l'anticorps parent à partir duquel ils ont été dérivés. Les anticorps inhibent l'interaction entre le tl1a et le récepteur de mort 3 (dr3). Les anticorps, ou une composition de ces derniers, peuvent être utilisés pour traiter une ou plusieurs affections parmi l'asthme, la bpco, la fibrose pulmonaire, la fibrose kystique, la maladie intestinale inflammatoire, une maladie gastro-intestinale associée à la fibrose kystique, la maladie de crohn, la colite, la colite ulcéreuse, le syndrome du côlon irritable, l'œsophagite à éosinophiles, la dermatite atopique, l'eczéma, la sclérodermie, l'arthrite ou la polyarthrite rhumatoïde.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220442P | 2015-09-18 | 2015-09-18 | |
| PCT/US2016/052040 WO2017049024A1 (fr) | 2015-09-18 | 2016-09-16 | Anticorps se liant spécifiquement à tl1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42825B1 true MA42825B1 (fr) | 2020-09-30 |
Family
ID=57043002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42825A MA42825B1 (fr) | 2015-09-18 | 2016-09-16 | Anticorps se liant spécifiquement à tl1a |
| MA052643A MA52643A (fr) | 2015-09-18 | 2016-09-16 | Anticorps se liant spécifiquement au tl1a |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052643A MA52643A (fr) | 2015-09-18 | 2016-09-16 | Anticorps se liant spécifiquement au tl1a |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US10138296B2 (fr) |
| EP (2) | EP3693393A1 (fr) |
| JP (2) | JP7013366B2 (fr) |
| KR (1) | KR101998535B1 (fr) |
| CN (1) | CN108137693B (fr) |
| AR (1) | AR106055A1 (fr) |
| AU (2) | AU2016323460B2 (fr) |
| BR (2) | BR112018005407A8 (fr) |
| CA (1) | CA2997015A1 (fr) |
| CL (1) | CL2018000711A1 (fr) |
| CO (1) | CO2018003736A2 (fr) |
| CY (1) | CY1123499T1 (fr) |
| DK (1) | DK3350223T3 (fr) |
| EA (1) | EA201890756A1 (fr) |
| ES (1) | ES2810751T3 (fr) |
| HR (1) | HRP20201323T1 (fr) |
| HU (1) | HUE051496T2 (fr) |
| IL (1) | IL257761B2 (fr) |
| LT (1) | LT3350223T (fr) |
| MA (2) | MA42825B1 (fr) |
| MD (1) | MD3350223T2 (fr) |
| MX (1) | MX2018003185A (fr) |
| PE (1) | PE20181080A1 (fr) |
| PH (1) | PH12018500580B1 (fr) |
| PL (1) | PL3350223T3 (fr) |
| PT (1) | PT3350223T (fr) |
| RS (1) | RS60703B1 (fr) |
| SI (1) | SI3350223T1 (fr) |
| SM (1) | SMT202000500T1 (fr) |
| TW (1) | TWI703158B (fr) |
| UA (1) | UA125284C2 (fr) |
| WO (1) | WO2017049024A1 (fr) |
| ZA (1) | ZA201801427B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| IL259752B (en) * | 2015-12-04 | 2022-07-01 | Univ Iowa Res Found | Device, systems and methods for prediction, screening and monitoring of encephalopathy / delirium |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| SG11201903737PA (en) | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| CA3061467A1 (fr) * | 2017-04-28 | 2019-10-24 | Ajinomoto Co., Inc. | Compose renfermant une substance ayant une affinite pour une proteine soluble, fraction clivable, et groupe reactif, ou sel de celui-ci |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| EP4048309A4 (fr) | 2019-10-24 | 2024-02-21 | Prometheus Biosciences, Inc. | Anticorps humanisés contre le ligand 1a de type tnf (tl1a) et leurs utilisations |
| EP4199953A4 (fr) * | 2020-08-19 | 2024-11-06 | Janssen Biotech, Inc. | Matériaux et procédés d'utilisation de ligands modifiés |
| KR20250044336A (ko) | 2022-07-27 | 2025-03-31 | 세파론 엘엘씨 | 궤양성 결장염 및 크론병의 치료를 위한 항-tl1a 항체 |
| WO2024026386A1 (fr) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Formulations d'anticorps anti-tl1a |
| WO2024239006A1 (fr) | 2023-05-17 | 2024-11-21 | Genentech, Inc. | Méthodesthérapeutiques à base d'anticorps anti-tl1a |
| TW202511288A (zh) * | 2023-06-22 | 2025-03-16 | 美商派拉岡醫療公司 | Il-23抗體組合物及使用方法 |
| TW202515910A (zh) * | 2023-06-22 | 2025-04-16 | 美商派拉岡醫療公司 | Il-17抗體組合物及使用方法 |
| WO2025038473A1 (fr) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Protéines de liaison à tl1a et procédés d'utilisation |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| CN120058933A (zh) * | 2023-11-30 | 2025-05-30 | 北京智仁美博生物科技有限公司 | 抗肿瘤坏死因子样配体1a的抗体及其用途 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| CN120424214A (zh) * | 2024-02-05 | 2025-08-05 | 三生国健药业（上海）股份有限公司 | 一种抗tl1a抗体及其制备方法和用途 |
| TW202540171A (zh) | 2024-02-06 | 2025-10-16 | 美商派拉岡醫療公司 | Ｉｌ－２３抗體組合物及使用方法 |
| CN120590530A (zh) * | 2024-03-05 | 2025-09-05 | 帆礼生物技术(武汉)有限公司 | 靶向tl1a的抗体及其应用 |
| WO2025240922A1 (fr) | 2024-05-17 | 2025-11-20 | Genentech, Inc. | Méthodes de traitement d'une maladie intestinale inflammatoire avec un anticorps anti-tl1a |
| CN119552252B (zh) * | 2025-01-16 | 2025-11-25 | 华润生物医药有限公司 | 抗tl1a抗体及其制备方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| ES2727425T3 (es) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| WO2005018571A2 (fr) | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions et procedes pour le traitement de la maladie pulmonaire inflammatoire |
| NZ550518A (en) | 2004-03-23 | 2009-11-27 | Biogen Idec Inc | Agents that cross link TNF receptors for treating cancer |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| CA2621083C (fr) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulation des agonistes, des antagonistes et des immunotoxines du recepteur 25 du facteur de necrose tumorale (tnfr25) |
| WO2007076465A2 (fr) | 2005-12-23 | 2007-07-05 | Diadexus, Inc. | Compositions d'anticorps anti-cln248 et leurs procédés d'utilisation |
| US9068003B2 (en) | 2007-01-10 | 2015-06-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| WO2008106451A2 (fr) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Procédés d'utilisation de polymorphismes nucléotidiques uniques dans le gène tl1a pour prédire ou diagnostiquer une affection intestinale inflammatoire |
| US20100240043A1 (en) | 2007-10-19 | 2010-09-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| EA020886B1 (ru) | 2007-11-13 | 2015-02-27 | ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. | Гуманизированные антитела против tl1a |
| WO2010118210A1 (fr) | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Méthodes de prévision d'une complication et d'une chirurgie dans la maladie de crohn |
| WO2011080314A2 (fr) | 2009-12-31 | 2011-07-07 | Deutsches Krebsforschungszentrum | Nouveaux modulateurs de signalisation par trail |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| US20140170157A1 (en) | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| BR112014007426B1 (pt) * | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| AU2013371957B2 (en) | 2013-01-02 | 2018-10-25 | Ichnos Sciences SA | Antibodies that bind to TL1A and their uses |
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| HK1220919A1 (zh) * | 2013-04-05 | 2017-05-19 | F. Hoffmann-La Roche Ag | 抗il-4抗体和双特异性抗体及其用途 |
| EP2996717A4 (fr) | 2013-05-17 | 2016-11-23 | Cedars Sinai Medical Center | Effets distincts d'ifn gamma et d'il-17 sur une inflammation et une fibrose modulées par tl1a |
| KR20250130857A (ko) | 2013-05-17 | 2025-09-02 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
| CA2922381A1 (fr) | 2013-09-06 | 2015-03-12 | Cedars-Sinai Medical Center | Systemes, dispositifs et procedes pour therapie anti-tl1a |
| AU2014348676B2 (en) | 2013-11-13 | 2020-06-18 | Bristol-Myers Squibb Company | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| DK3283499T5 (da) | 2015-04-15 | 2024-09-16 | Biosearch Tech Inc | Dual quencher probes |
| WO2016186972A1 (fr) | 2015-05-15 | 2016-11-24 | Cedars-Sinai Medical Center | Modèles, méthodes et compositions pour traiter une infection intestinale inflammatoire |
| WO2017035010A1 (fr) | 2015-08-21 | 2017-03-02 | The Children's Hospital Of Philadelphia | Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| WO2017077715A1 (fr) | 2015-11-02 | 2017-05-11 | La Jolla Institute For Allergy & Immunology | Procédé et médicament pour traiter des maladies des voies respiratoires et/ou pulmonaires |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| AU2017264578A1 (en) | 2016-05-09 | 2019-01-03 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| IL263406B2 (en) | 2016-06-09 | 2023-09-01 | Pelican Therapeutics Inc | Anti-tnfrs25 antibodies |
| SG11201903737PA (en) | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US10626180B2 (en) | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| CA3098720A1 (fr) | 2018-04-30 | 2019-11-07 | Cedars-Sinai Medical Center | Procedes et systemes de selection et de traitement de patients souffrant de maladies inflammatoires |
| CA3121167A1 (fr) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Procedes de classification et de traitement d'une sous-population de patients atteints d'une maladie intestinale inflammatoire |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| TWI871367B (zh) | 2019-10-24 | 2025-02-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a(tl1a)之人類化抗體及其用途 |
| EP4065727A4 (fr) | 2019-11-27 | 2024-03-27 | Cedars-Sinai Medical Center | Prédiction de manifestations extra-intestinales de maladies intestinales inflammatoires |
| US20230279491A1 (en) | 2020-06-03 | 2023-09-07 | Cedars-Sinai Medical Center | Treatments for a sub-population of inflammatory bowel disease patients |
| WO2021247770A1 (fr) | 2020-06-03 | 2021-12-09 | Cedars-Sinai Medical Center | Méthodes et systèmes de mesure de la récurrence d'une maladie après opération |
| BR112022025667A2 (pt) | 2020-06-26 | 2023-03-07 | Pfizer | Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a |
| WO2022103961A1 (fr) | 2020-11-13 | 2022-05-19 | Prometheus Biosciences, Inc. | Méthodes, systèmes et kits pour le traitement d'une maladie inflammatoire ciblant tl1a |
| WO2022119842A1 (fr) | 2020-12-01 | 2022-06-09 | Cedars-Sinai Medical Center | Procédés et systèmes pour stratification de patients atteints de maladie inflammatoire |
| EP4263585A4 (fr) | 2020-12-21 | 2024-11-27 | Cedars-Sinai Medical Center | Compositions thérapeutiques de tl1a et méthodes de traitement les utilisant |
| JP2024506940A (ja) | 2021-02-18 | 2024-02-15 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 |
| CA3207818A1 (fr) | 2021-02-18 | 2022-08-25 | Allison LUO | Compositions d'anticorps anti-tl1a et methodes de traitement pulmonaire |
| WO2022232253A1 (fr) | 2021-04-28 | 2022-11-03 | Cedars-Sinai Medical Center | Procédés et kits de sélection des patients pour thérapies ciblant tl1a |
| WO2023102071A1 (fr) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Métabolites microbiens contre l'inflammation intestinale |
| WO2023102051A1 (fr) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Phagocytes mononucléaires intestinaux en tant que biomarqueur de pronostic pour la maladie de crohn |
| WO2023133538A2 (fr) | 2022-01-07 | 2023-07-13 | Prometheus Biosciences, Inc. | Méthodes de traitement de maladies inflammatoires avec combinaison d'inhibiteurs de tl1a et d'inhibiteurs d'il23 |
| US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
-
2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
- 2016-09-16 CA CA2997015A patent/CA2997015A1/fr active Pending
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/fr active Pending
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 SM SM20200500T patent/SMT202000500T1/it unknown
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
- 2016-09-16 HR HRP20201323TT patent/HRP20201323T1/hr unknown
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active Active
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/fr not_active Ceased
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/fr active Active
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 BR BR112018005407A patent/BR112018005407A8/pt active IP Right Grant
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 PH PH1/2018/500580A patent/PH12018500580B1/en unknown
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt not_active Application Discontinuation
-
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
-
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
-
2021
- 2021-11-30 US US17/538,530 patent/US12162946B2/en active Active
-
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
-
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440A1/en active Pending
-
2024
- 2024-11-06 US US18/939,176 patent/US20250179202A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42825B1 (fr) | Anticorps se liant spécifiquement à tl1a | |
| WO2018194496A3 (fr) | Anticorps monoclonal à pd-l1 | |
| CL2018003556A1 (es) | Anticuerpos anti-ige. | |
| MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
| MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
| CA3156451A1 (fr) | Anticorps ayant une specificite pour la nectine -4 et leurs utilisations | |
| MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
| MY201701A (en) | Optimized antibody compositions for treatment of ocular disorders | |
| NZ746002A (en) | Antibody-containing preparation | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| MA42439B1 (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
| MX392069B (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| FR3020766B1 (fr) | Particules inorganiques individualisees | |
| PE20190208A1 (es) | Anticuerpos que reconocen tau | |
| JOP20200157A1 (ar) | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 | |
| MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
| MA40378B1 (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine | |
| FR3045384B1 (fr) | Composition lyophilisee pour la conservation de microbiote dans son ecosysteme | |
| MA39821B1 (fr) | Molécules de liaison spécifiques de l'il-21 et leurs utilisations | |
| MA42440B1 (fr) | Anticorps contre la sortilin qui inhibent la liason à la progranulin | |
| WO2009000929A3 (fr) | Composition et procédé de traitement de maladie auto-immune | |
| MA34483B1 (fr) | Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos |